Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 328 participants.
Also called NCT02203916
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 328 participants
- Sponsor
- Registry
-
NCT02203916
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02203916. Randomized; quadruple masking; primary purpose treatment. Start 2014-07 (registry gives no type); primary completion 2016-01 (actual). Results posted on 2016-12-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension
- Condition
- Hypertension
- Intervention (Drug)
- Azilsartan medoxomil
- Intervention (Drug)
- Azilsartan medoxomil placebo
- Lead sponsor
- Takeda
Record details
- Record id
cardio:ct-nct02203916- Content hash
d3966b7f291094dcc54dd9c55e27d61101e8dff3d032f86c21c913ae7fd5ec0e